TrialTargeted oncology2015

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Josep Tabernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.